Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-45

A great find Stecam44. I notice there is also a link at the site to the transcript which can then be downloaded as a pdf.

The statement you are referring to is -

“ .. we have early data to support this, we haven't released it yet, but we'll see, is that when our compound is used earlier, the selectivity of bacteria fighting against the existing antibiotics may be reversed ... “

Certainly interesting.

Being “early data” it would presumably not yet be confirmed and there is no reason as such why it should have been disclosed to the market yet. Indeed, any company undertaking scientific research would be generating new data in the laboratories just about every day and there would be no requirement to provide ongoing research reports concerning it.

poorinvestor